Leadership

Home  >  About  >  Leadership

Executive Team

Portrait

Craig A. Wheeler, President and Chief Executive Officer

See bio

Mr. Wheeler joined Momenta as CEO in September of 2006. He led the company through the launch of its first complex drug products, including the first generic versions of LOVENOX® and once-daily COPAXONE®. He has overseen the company’s growth into the diversified business it is today. In 2011, he was an E&Y Entrepreneur of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta the number one company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr. Wheeler was President of Chiron BioPharmaceuticals where during his five-year tenure the pharmaceutical division’s global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group’s health care practice and worked extensively in the health care sector. He began his career at Merck’s MSDRL research unit. Mr. Wheeler is currently a member of the Board of Directors of Amicus Therapeutics as well as, where he serves Chairman of the Science Committee. He previously was on the board of the Association for Accessible Medicines (AAM)), where he previously served as Chairman from 2014 to February 2016. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion.

Portrait

Santiago Arroyo,, M.D., Ph.D., Senior Vice President, Development and Chief Medical Officer

See bio

Dr. Arroyo joined Momenta in June of 2017. He is responsible for preclinical and clinical development and regulatory affairs. He joins Momenta from Boston Pharmaceuticals, where he was Chief Medical Officer. Previously he was Senior Vice President, Head of Clinical Research and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc. in the areas of Cardiovascular and Metabolism, Pain, Neuroscience, Regenerative Medicine and Rare Diseases. He was previously Therapeutic Area Head for Neurosciences, Discovery Medicine and Clinical Pharmacology at Bristol-Myers Squibb and Neurology Global Therapeutic Area Head for Eisai Global Clinical Development. Dr. Arroyo was an Instructor in Neurology at the Johns Hopkins Hospital and Associate Professor of Neurology and Director of the Epilepsy Program at the Medical College of Wisconsin and at the Hospital Clinic of Barcelona, Spain. Dr. Arroyo received his medical degree from the Autonomous University of Madrid and his Ph.D. from the University of Barcelona, Spain.

Portrait

Jo-Ann Beltramello, Chief Human Resources and Infrastructure Officer

See bio

Ms. Beltramello joined Momenta in October of 2007. Ms. Beltramello is responsible for all human resources, IT, and facilities matters for the company. She was previously the Chief Human Resources Officer at Multiplan, a provider of health care cost management solutions with over 2,000 employees conducting business in all fifty states. In this role, she was responsible for all human resource operations, including strategy, policies and program development. Prior to joining Multiplan, she held senior human resources roles at Private Healthcare Systems, Inc., Oxford Global Resources, Inc., and Randstad North America.

Portrait

Alejandra Carvajal, Chief Legal Officer and General Counsel

See bio

Alejandra V. Carvajal, J.D., joined Momenta as Vice President, Deputy General counsel in June 2017 and has served as the company's Chief Legal Officer, General Counsel & Secretary since October 2018. Ms. Carvajal is responsible for all legal matters and operations at the company.  Prior to joining Momenta, Ms. Carvajal was Vice President and General Counsel of Cerulean Pharma, a public biotechnology company, from September 2014 until June 2017.  Prior to Cerulean, Ms. Carvajal worked at Millennium: The Takeda Oncology Company from 2004 to 2014, where she held a variety of legal positions of increasing seniority. Ms. Carvajal began her legal career in private practice with the law firms of Day, Berry &Howard and Hill & Barlow. Ms. Carvajal received a B.A. cum laude from Harvard University and a J.D. cum laude from Georgetown University Law Center.

Portrait

Ian D. Fier, Chief Manufacturing and Program Officer

See bio

Mr. Fier joined Momenta in October of 2002. Mr. Fier is responsible for overseeing our bioprocess development, analytical development and quality functions, manufacturing technical operations, and program and portfolio management. He was previously Vice President of Clinical Affairs at BioTransplant Inc. where he led a clinical development group responsible for the development and commercialization of both antibody-based therapeutics and medical devices. Prior to that, he held positions in product development and project management at Hoechst-Roussel (now Sanofi Aventis), Astra USA and The Medicines Company and was involved with the development and launch of several successful products. Mr. Fier received his BS from Tufts University and a MBA with a concentration in Heath Care Management from Boston University.

Portrait

Young Kwon,, Ph.D., Chief Financial and Business Officer

See bio

Dr. Kwon became Chief Financial and Business Officer in January 2020 and has responsibility for finance, corporate and business development, corporate strategy, investor relations, and commercial. He joined Momenta in 2011. Prior to Momenta, he was at Biogen Idec in business and corporate development, where he completed late-stage clinical licensing transactions and other deals. In addition, he worked at Advanced Technology Ventures, a venture capital firm, where he identified and invested in early-stage life science companies. He has a Ph.D from Harvard University, where he has co-authored numerous peer-reviewed publications in the area of neurobiology, and an undergraduate degree from MIT.

Portrait

Anthony Manning,, Ph.D., Chief Scientific Officer

See bio

Dr. Manning joined Momenta in January 2013. He is responsible for research and driving the discovery of novel products. Since joining Momenta, his teams have advanced three novel autoimmune drugs nipocalimab (M281), M230, and M254 into development and implemented a research engine to discover novel, first-in-class therapeutics for rare immune-related diseases. Prior to Momenta, Dr. Manning was Senior Vice President of Research and Preclinical Development at Aileron Therapeutics. Before that, he was Vice President and Head of Immunology Research for Biogen Idec, Inc. Before that, he was Vice President and Global Head of Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals.

Boards of Directors

Jane F. Barlow,, M.D., M.P.H., M.B.A.

See bio

Jane F. Barlow, M.D., M.P.H., M.B.A., has been a director since December 2019. Dr. Barlow is currently the chief executive officer of Jane Barlow & Associates, LLC, executive vice president and chief clinical officer at Real Endpoints and board director at TherapeuticsMD. Previously, she was associate chief medical officer at CVS Health and chief medical officer of CVS Health’s Government Services arm where she successfully implemented industry-leading clinical strategies. Prior to working at CVS Health, she served as vice president of clinical innovation at MEDCO Health Solutions. Dr. Barlow received her M.D. from Creighton University and completed her residency in occupational and environmental medicine at The Johns Hopkins University, where she also earned her M.P.H. Additionally, she holds an M.B.A. from the University of Alabama and is a distinguished graduate of the United States Air Force School of Aerospace Medicine. She is board-certified in occupational medicine and is a fellow of both the American College of Occupational and Environmental Medicine and the American College of Preventive Medicine. Dr. Barlow’s qualifications to sit on the board include 25 years of experience as a clinical and strategic senior healthcare executive and her expertise in creating innovative medical and pharmaceutical access strategies.

Bruce Downey, Chairman

See bio

Bruce L. Downey has been a director since June 2009 and has served as chairman of the board since June 2018. Mr. Downey has served as a partner at NewSpring Capital, a venture capital firm, since April 2009. Previously, Mr. Downey was chairman and chief executive officer of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company that operated in more than 30 countries worldwide and was acquired by Teva Pharmaceutical Industries Ltd. in 2008. Mr. Downey is a member of the board of directors of Cardinal Health, Inc., serving on the nominating and governance committee, as well as the board of directions of Melinda Therapeutics, serving on the audit and nominating and governance committees. Mr. Downey graduated with honors from Miami University in 1969 and received his law degree, cum laude, from Ohio State. Mr. Downey’s qualifications to sit on the board include his significant experience serving as a chief executive officer of a global generic pharmaceutical company that also had a substantial brand business and an active biologics research and development program, his years serving as a lawyer in private practice and his experience serving on other boards of directors in the biopharmaceutical industry.

Georges Gemayel,, Ph.D.

See bio

Georges Gemayel, Ph.D., has been a director since January 2016. Since 2010, he has served as a consultant for several biotechnology companies and venture capital funds. From February 2011 to December 2012, Dr. Gemayel served as executive chairman of Syndexa Pharmaceuticals Corp., a privately held drug development company. Prior to that, in 2010, Dr. Gemayel served as executive chairman of FoldRx Pharmaceuticals, Inc. until its acquisition by Pfizer Inc. From June 2008 until November 2009, Dr. Gemayel served as president and chief executive officer of Altus Pharmaceuticals Inc., a publicly traded pharmaceutical company. Dr. Gemayel received his doctorate in pharmacy from St. Joseph University in Beirut, Lebanon, and his Ph.D. in pharmacology from Paris‑Sud University in Paris, France. Dr. Gemayel currently serves as chairman of the boards of directors of several privately held companies, and on the boards of directors of Orphazyme ApS and Supernus Pharmaceuticals, Inc., which are publicly traded biotechnology companies. He was previously a director of publicly traded biotechnology companies, Dimension Therapeutics, Inc., which was acquired by Ultragenyx Pharmaceuticals, Inc., Raptor Pharmaceuticals, Inc., which was acquired by Horizon Pharma plc, Adolor Corporation, which was acquired by Cubist Pharmaceuticals, Inc., Prosensa Holding N.V., which was acquired by BioMarin Pharmaceutical Inc. and NPS Pharmaceuticals, Inc., which was acquired by Shire plc. Dr. Gemayel’s qualifications to sit on the board include his over 25 years of experience in the biopharmaceutical industry, including management and executive positions.

Steven C. Gilman,, Ph.D.

See bio

Steven C. Gilman, Ph.D., has been a director since June 2016. In 2016, Dr. Gilman was appointed as the chief executive officer and the chairman of the board of directors of ContraFect Corporation, a publicly traded biotechnology company. Until 2015, he served as the executive vice president, Research & Development and chief scientific officer at Cubist Pharmaceuticals, a biopharmaceutical company, until its acquisition by Merck & Co. Before joining Cubist in 2008, Dr. Gilman served as chairman of the board of directors and chief executive officer of ActivBiotics, a privately held biopharmaceutical company. In addition to his service on ContraFect Corporation’s board of directors, Dr. Gilman currently serves on the boards of directors of publicly traded biotechnology companies, Keryx Biopharmaceuticals, Inc., serving on the research and development and audit committees, SCYNEXIS Inc., serving on the nominating and corporate governance and audit committees, and Vericel Corporation, serving on the compensation committee. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post‑doctoral training at Scripps Clinic and Research Foundation, and a B.A. in microbiology from Miami University of Ohio. Dr. Gilman’s qualifications to sit on the board include his leadership experience in the biopharmaceutical industry, including his senior executive positions at ContraFect and Cubist and his experience serving on other boards of directors in the biotechnology industry.

Donna Roy Grogan,, M.D.

See bio

Donna Roy Grogan, M.D., has been a director since September 2019. Dr. Grogan, who is now Principal, Grogan Consulting LLC, previously served as chief medical officer of Clementia Pharmaceuticals, Inc. (acquired by Ipsen in April 2019), a biopharmaceutical company innovating new treatments for ultra-rare bone disorders and other diseases. Prior to working at Clementia, Dr. Grogan served as the chief medical officer for several Health Care Venture focused companies including Anexon, Apofore and DecImmune. She previously worked at FoldRx Pharmaceuticals (acquired by Pfizer in October 2010) as chief medical officer. and at Sepracor (now Sunovion) where she was Senior Vice President Clinical Research at her departure. She has made significant contributions to numerous successful NDAs, including Lunestaâ, Xopenex HFAâ, BrovanaTM and most recently the EMA authorization of Vyndaqelâ (tafamidis) for the treatment of the rare neurologic disease Transthyretin Familial Amyloid Polyneuropathy. Dr. Grogan received her B.A. from College of the Holy Cross and earned her M.D. from University of Illinois College of Medicine. Dr. Grogan’s qualifications to sit on the board include her 15 years of experience as a board-certified physician, her leadership in numerous investigational new drug applications and her expertise in the design and execution of clinical programs across multiple therapeutic areas, including rare diseases.

Jose-Carlos (JC) Gutierrez-Ramos,, Ph.D.

See bio

Jose‑Carlos Gutiérrez‑Ramos, Ph.D., has served as a director since March 2016. Since 2015, he has served as chief executive officer and president of Synlogic, Inc., a pharmaceutical company. Prior to joining Synlogic, Dr. Gutiérrez‑Ramos was group senior vice president of Worldwide Research and Development and global head of Biotherapeutics Research and Development at Pfizer Inc., a pharmaceutical company, from 2010 to 2015. Dr. Gutiérrez‑Ramos received a B.S. from Universidad Complutense de Madrid and his Ph.D. in immunochemistry from the Universidad Autonoma de Madrid. Dr. Gutiérrez‑Ramos’ qualifications to sit on the board include his senior executive experience in the pharmaceutical industry, including his significant experience in research and development.

Elizabeth Stoner,, M.D.

See bio

Dr. Elizabeth (Liz) Stoner, has been a director since October 2007. She is a distinguished biopharma executive, who brings decades of international industry experience to her role guiding and growing MPM portfolio companies. She is currently Senior Clinical Advisor of AlloVir, an ElevateBio company, and was most recently the company’s interim CMO. She also serves as Senior Clinical Advisor to Rhythm Pharmaceuticals. Liz has held several leadership roles at MPM portfolio companies including interim CEO of Semma Therapeutics; founder, CMO and Chief Development Officer (CDO) of Rhythm and the CDO of Vascular Pharmaceuticals. She also served in clinical and advisory roles at Clinical Ink, Potenza Therapeutics, Solasia and TriNetX. Liz is a member of the Cures Acceleration Network Review Board of the National Center for Advisory Translations Sciences of the NIH to represent viewpoints of drug development and venture capital professionals regarding the discovery and development of therapeutics, diagnostics and devices.

Prior to joining MPM, Liz was Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries. While at Merck, she also oversaw the clinical development activities of its Japanese subsidiary and played a leading role in Merck/Schering Plough Joint Venture’s development of Vytorin and Zetia, blockbuster cholesterol lowering drugs. Previously, she led the 5-alpha reductase clinical development program, establishing Merck as a leader in the field of prostate disease. As Endocrine Therapeutic Head at Merck, her responsibilities included all steroid and lipid metabolism, as well as the bisphosphonate and growth hormone secretagogue clinical research programs. Prior to joining the biopharma industry, she was an Assistant Professor of Pediatrics at Cornell University Medical College. Liz currently serves on the boards of Vascular Pharmaceuticals and Momenta Pharmaceuticals. She is also a member of the Albert Einstein College of Medicine Board of Governors, and the Weill Cornell Medical College Clinical and Translational Science Center External Advisory Board.

Liz received her M.D. from the Albert Einstein College of Medicine, her M.S. in Chemistry from SUNY at Stony Brook and her B.S. in Chemistry from Ottawa University, KS.

Craig A. Wheeler

See bio

Craig A. Wheeler has served as our president and a director since August 2006 and was appointed our chief executive officer effective September 2006. Prior to joining Momenta, Mr. Wheeler served as president of Chiron Biopharmaceuticals, a division of Chiron Corporation, a biotechnology company, from August 2001 until June 2006. Mr. Wheeler serves on the board of Amicus Therapeutics, Inc., including serving on the science and compensation committees. Mr. Wheeler served as a director of Avanir Pharmaceuticals, Inc., which was acquired by Otsuka Pharmaceuticals Co., Ltd., from September 2005 to January 2015, including serving on the corporate governance and audit committees, and serving as chairman of the board beginning May 2007. Mr. Wheeler has been a member of the board of the Association for Accessible Medicines, formerly known as the Generic Pharmaceutical Association, for over eight years, including serving as chairman of the board from 2014 to 2016 and as a member of the executive committee for the past six years. Mr. Wheeler received B.S. and M.S. degrees in chemical engineering from Cornell University and an M.B.A. degree from the Wharton School of the University of Pennsylvania. Mr. Wheeler’s qualifications to sit on the board include his years of senior executive management experience in the biotechnology industry, including over ten years as our president and chief executive officer, and his experience serving on other boards of directors in the biotechnology industry.